Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention - Sharma, M; Molina, CA; Toyoda, K (J Stroke Cerebrovasc Dis, 2022)